LAS VEGAS — Dr. Cindy Orser, the Chief Science Officer of DigiPath Labs, a subsidiary of DigiPath, Inc.(OTCQB: DIGP) will be a featured speaker at the Emerald Conference in Las Vegas on Thursday, January 21. Dr. Orser’s talk, entitled “Ensuring Patient Safety & Establishing Standardization in Cannabis Testing,” is scheduled for 1:30 p.m.
Dr. Orser will cover the evolution of quality assurance testing in the State of Nevada as compared to the rest of the country and the need for standardization of cannabis testing for both recreational and medical cannabis across the United States. Dr. Orser will also unveil DigiPath Labs’ plans to partner with a leading organization in linking cannabis chemotypes with genotyping of cannabis strains.
The Emerald Conference is devoted to the exploration and discussion of the science of cannabis including analytical testing, R&D, clinical applications, inter-lab comparison and proficiency testing, state regulations, industry standardization, and more.
“I urge everyone concerned with the future of the cannabis industry to keep their calendars open for this event,” commented Dr. Orser. “This conference will present a refreshing perspective.”
The event will be held at the Monte Carlo Resort & Casino conference center in Las Vegas, Nevada. The event will draw participants across a wide spectrum of disciplines, including chemists, clinicians, policy makers, cultivators, and dispensary owners. The Emerald Conference aims to share the latest in research and technologies in the cannabis industry in a collegial atmosphere. Tickets are available at https://www.eventbrite.com/e/2016-emerald-conference-tickets-17767069784.
To learn more about DigiPath Labs, visit www.digipathlabs.com.
About DigiPath, Inc.
DigiPath, Inc., supports the cannabis industry’s best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath’s two business units are DigiPath Labs and TNM News Corp.
For more information, go to www.digipath.com.
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the demand for the Company’s products, governmental regulation of the cannabis industry, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE DigiPath, Inc.